Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $7.10, but opened at $6.39. Mesoblast shares last traded at $6.53, with a volume of 84,636 shares traded.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on MESO. StockNews.com downgraded shares of Mesoblast from a "hold" rating to a "sell" rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald restated an "overweight" rating on shares of Mesoblast in a research report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Mesoblast presently has a consensus rating of "Hold" and a consensus price target of $13.67.
Get Our Latest Stock Report on MESO
Mesoblast Trading Down 7.0 %
The stock's 50-day moving average is $3.89 and its 200-day moving average is $2.78. The company has a market cap of $753.59 million, a price-to-earnings ratio of -5.89 and a beta of 3.59.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Mesoblast stock. Lazari Capital Management Inc. lifted its stake in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) by 9.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 94,034 shares of the company's stock after acquiring an additional 8,000 shares during the period. Lazari Capital Management Inc. owned 0.06% of Mesoblast worth $116,000 at the end of the most recent reporting period. 1.43% of the stock is currently owned by hedge funds and other institutional investors.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
